|
Impact of surgery versus other treatment options in recurrent glioblastoma. Analysis of the Spanish Group of Neurooncology Research (GEINO) RETSINE database. |
|
María Ángeles Vaz Salgado |
Consulting or Advisory Role - PharmaMar |
Research Funding - Pfizer |
|
|
Consulting or Advisory Role - Merck KGaA; Roche |
Speakers' Bureau - Bristol-Myers Squibb/Celgene; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Merck; Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Pfizer; Pierre Fabre; Roche; Tesaro |
|
Maria Teresa Quintanar Verduguez |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Maria Teresa Tuñón Alvarez |
No Relationships to Disclose |
|
Alberto Jacobo Cunquero Tomas |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
José Manuel Sepulveda Sánchez |
Consulting or Advisory Role - Abbvie; Celgene; GW Pharmaceuticals; IDP Pharmaceuticals; Pfizer |
Research Funding - IDP Pharmaceuticals; Pfizer |
Travel, Accommodations, Expenses - Abbvie; Ipsen; Pfizer |
|
|
No Relationships to Disclose |
|
Pablo Alvarez-Ballesteros |
Speakers' Bureau - PharmaMar |
|
Ramon De Las Peñas Bataller |
No Relationships to Disclose |